SCHEMBL8908162

SCHEMBL8908162

CCCCOC(=O)N(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 4/20 0.58
CHRNA4 P43681 4/20 0.58
CHRM2 P08172 2/20 0.58
CHRM4 P08173 2/20 0.58
CHRM5 P08912 2/20 0.58
CHRM1 P11229 2/20 0.58
CHRM3 P20309 2/20 0.58
ALDH1A1 P00352 3/20 0.56
ATM Q13315 1/20 0.52
TSHR P16473 4/20 0.48
HPGD P15428 2/20 0.48
HCAR2 Q8TDS4 1/20 0.45
NAAA Q02083 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
MAPK1 P28482 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12807165 0.93 CHRNB2 (0.56) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL27915971 0.91 NAAA (0.57) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL29979958 0.91 NAAA (0.57) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL25277070 0.91 NAAA (0.57) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL29980053 0.91 NAAA (0.57) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL25272656 0.91 NAAA (0.57) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL8372851 0.91 NAAA (0.57) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL28052298 0.89 NAAA (0.55) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL29197969 0.89 NAAA (0.55) CHRNB2CHRNA4CHRM2CHRM4CHRM5
Ammonia Solution, Strong SCHEMBL27850802 0.89 NAAA (0.55) CHRNB2CHRNA4CHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
US-20240158337-A1 GAS-PHASE OXIDATIVE COUPLING OF ALCOHOLS AND AMINES USING HETEROGENEOUS CATALYSTS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA 2024-05-16 US disclosed
WO-2023106377-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND 旭化成株式会社 2023-06-15 WO disclosed
US-9616099-B2 Cyclosporin analogues for preventing or treating hepatitis C infection ENANTA PHARMACEUTICALS, INC. (US) 2017-04-11 US disclosed
US-20160136233-A1 NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION ENANTA PHARM INC (US) 2016-05-19 US disclosed
US-9221878-B2 Cyclosporin analogues for preventing or treating hepatitis C infection ENANTA PHARMACEUTICALS, INC. (US) 2015-12-29 US disclosed
EP-2568019-B1 Inkjet ink JNC CORP (JP) 2015-09-02 EP disclosed
US-9040625-B2 Water/oil repellent composition, method for its production and article ASAHI GLASS COMPANY, LIMITED (JP) 2015-05-26 US disclosed
US-20150056165-A1 NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION ENANTA PHARMACEUTICALS, INC. 2015-02-26 US disclosed
US-20140051797-A1 WATER/OIL REPELLENT COMPOSITION, METHOD FOR ITS PRODUCTION AND ARTICLE ASAHI GLASS COMPANY, LIMITED (JP) 2014-02-20 US disclosed
US-20130281476-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED 2013-10-24 US disclosed
US-8497295-B2 Spiroindoline modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-30 US disclosed
EP-2568019-A1 Inkjet ink JNC Corporation (JP) 2013-03-13 EP disclosed
US-7858635-B2 Spiro compounds as modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-28 US disclosed
US-20080015179-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
EP-0575191-B1 Non-aqueous electrolyte solvent and battery containing this electrolyte MITSUI PETROCHEMICAL IND (JP) 1997-08-27 EP disclosed
US-5434290-A Carbonylation of 1-cyanobut-2-ene with carbon monoxide and alkanol in presence of cobalt catalyst and activating organic carbonate solvent BASF AKTIENGESELLSCHAFT (DE) 1995-07-18 US disclosed
US-5385794-A Lithium battery; carbamate and cyclic carbonate solvents MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) 1995-01-31 US disclosed
EP-0575191-A1 Non-aqueous electrolyte solvent and battery containing this electrolyte MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1993-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281476-A1 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 CHRNB2 16/4885CHRNA4 14/4885CHRM2 3/4885
US-20160136233-A1 NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION HAVCR2, CHP1, MAVS CHRNB2 4786/4885CHRNA4 4700/4885CHRM2 4794/4885
US-20080015179-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 CHRNB2 16/4885CHRNA4 14/4885CHRM2 3/4885
US-20150056165-A1 NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION HAVCR2, CHP1, MAVS CHRNB2 4786/4885CHRNA4 4700/4885CHRM2 4794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.